title: Intra-lesional 5 fluorouracil for the management of recurrent pterygium.
abstract: OBJECTIVE
  Recurrence is the most common complication arising from pterygium surgery. The aim of this study was to investigate the effectiveness of 5 fluorouracil (5FU) in halting the recurrence of pterygium after surgical excision.
  
  
  METHODS
  A retrospective review of patients treated for pterygium recurrence was carried out. Patients with recurrent (secondary) pterygium were treated with multiple weekly intra-lesional injections of 0.1-0.2 ml (2.5-5 mg) 5FU post-operatively depending on the size of the recurrence. The treatment was started within 1 month from the date of recurrence. The time from surgery to start of recurrence, previous treatment modalities, and number of recurrences were documented. The number of injections required to induce arrest of progression and/or regression of vascularity and fleshiness of the pterygium and any complications related to 5FU treatment were examined.
  
  
  RESULTS
  Fifteen eyes from 14 patients with recurrent pterygium treated with intra-lesional 5FU injections were analysed. Three of the 15 eyes had undergone a secondary excision and 12 had undergone a primary excision. In all, 93.3% of patients showed regression of the fibrovascular tissue (thickness and vascularity) and arrest of progression following a dose of 0.1-0.2 ml (2.5-5 mg) 5FU. Twelve eyes required three injections or fewer, whereas one patient required eight injections. This beneficial effect was maintained over an average follow-up period of 17 months. No complications from 5FU were observed.
  
  
  CONCLUSIONS
  The use of weekly intra-lesional 5FU injections for the treatment of recurrent pterygium is safe and effective in limiting the progression and inducing the regression of recurrent pterygium. The number of injections can be tailored according to clinical need.
authors.affiliation: 1] Department of Ophthalmology, Nottingham University Hospitals, University of Nottingham, Nottingham, UK [2] Cornea and Ocular Surface Unit, Research Institute of Ophthalmology, Cairo, Egypt.
authors.forename: D G
authors.initials: DG
authors.lastname: Said
authors.forename: L A
authors.initials: LA
authors.lastname: Faraj
authors.forename: M S
authors.initials: MS
authors.lastname: Elalfy
authors.forename: A
authors.initials: A
authors.lastname: Yeung
authors.forename: A
authors.initials: A
authors.lastname: Miri
authors.forename: U
authors.initials: U
authors.lastname: Fares
authors.forename: A M
authors.initials: AM
authors.lastname: Otri
authors.forename: I
authors.initials: I
authors.lastname: Rahman
authors.forename: S
authors.initials: S
authors.lastname: Maharajan
authors.forename: H S
authors.initials: HS
authors.lastname: Dua
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011625:Pterygium / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D055502:Secondary Prevention
chemical_list: D007166:Immunosuppressive Agents; D005472:Fluorouracil